Edoxaban versus enoxaparin for the prevention of venous thromboembolism after total knee or hip arthroplasty: pooled analysis of coagulation biomarkers and primary efficacy and safety endpoints from two phase 3 trials

Table 1 Patient demographics and baseline characteristics

Variable	Edoxaban 30 mg QD N = 657	Enoxaparin 20 mg BID N = 650	P value
Female, n (%)	552 (84.0)	527 (81.1)	0.161^a
Age, years, mean (min–max)	68.3 (36–84)	68.1 (24–84)	0.760^b
Body weight, kg, mean (min–max)	58.7 (40–124)	58.8 (40–98)	0.848^b
Creatinine clearance, mL/min, mean (min–max)	82.1 (30.6–242.9)	81.7 (31.0–209.7)	0.804^b
Primary disease, n (%)
Osteoarthritis	582 (88.6)	563 (86.6)	0.270^c
Rheumatoid arthritis	42 (6.4)	46 (7.1)
Other	35 (5.0)	41 (6.3)

ISSN: 1477-9560